Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m(2)) and dexamethasone (once-weekly Kd70 mg/m(2)) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m(2)) and dexamethasone (twice-weekly Kd27 mg/m(2)) in patients with relaps...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Cancer J
Hoofdauteurs: Dimopoulos, Meletios A., Niesvizky, Ruben, Weisel, Katja, Siegel, David S., Hajek, Roman, Mateos, María-Victoria, Cavo, Michele, Huang, Mei, Zahlten-Kumeli, Anita, Moreau, Philippe
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7062899/
https://ncbi.nlm.nih.gov/pubmed/32152297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0300-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items